Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose

What this Trial Is About

Researchers are evaluating whether a brief infusion of angiotensin II (AT-II) can improve the effectiveness of yttrium-90 (90Y) radioembolization in treating primary or metastatic liver tumors. This Phase 2 clinical trial aims to determine if angiotensin II helps more radioactive beads reach the tumor while sparing healthy liver tissue, as well as to assess the safety of combining angiotensin II with the standard radioembolization treatment. Participants receive standard yttrium-90 radioembolization where angiotensin II is given directly into the hepatic artery just before injecting the radioactive beads at each treatment site. If multiple arterial sites require treatment, angiotensin II is administered at each location. For cases needing whole-liver treatment in two sessions, angiotensin II is given during both. The angiotensin II infusion is delivered at 10 micrograms per minute for 100 seconds per injection site. Participants undergo a work-up visit including injection of a radioactive tracer and a SPECT/CT scan to observe tracer distribution in the liver. After 2 to 3 weeks, they receive the treatment with angiotensin II and yttrium-90 beads. Following treatment, a PET/CT scan is performed to compare bead distribution to the initial tracer scan. Routine monitoring of vital signs occurs during the procedure, with no extra hospital visits beyond standard care. The main outcome is the improvement in tumor-to-non-tumor dose ratio measured between baseline and post-treatment imaging.

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)